Biomarker Analyses from a Phase Iii, Randomized, Open-Label, First-Line Study of Gefitinib (G) Versus Carboplatin/Paclitaxel (C/P) in Clinically Selected Patients (Pts) with Advanced Non-Small Cell Lung Cancer (Nsclc) in Asia (Ipass)

腫瘤醫學研究所YANG, CHIH-HSINCHIH-HSINYANG2011-06-242018-07-092011-06-242018-07-092009http://ntur.lib.ntu.edu.tw//handle/246246/235713en-US[SDGs]SDG3Biomarker Analyses from a Phase Iii, Randomized, Open-Label, First-Line Study of Gefitinib (G) Versus Carboplatin/Paclitaxel (C/P) in Clinically Selected Patients (Pts) with Advanced Non-Small Cell Lung Cancer (Nsclc) in Asia (Ipass)